Applicants Sought for New Medical Study to Research Use of SinuSonic in the Effective Treatment of Viral Upper Respiratory Infections

COLUMBIA, S.C., October 12, 2020 – Developers of SinuSonic, a first of its kind medical device for natural relief of nasal congestion using acoustic humming and oscillating pressure, are seeking applicants for a new independent medical study in coordination with researchers at the Medical University of South Carolina. The study will aid researchers in determining the efficacy of SinuSonic for preventing viral upper respiratory infections.

Upper respiratory infections are commonly caused by viruses such as influenza, rhinovirus, and coronaviruses. “Nitric oxide has been shown to have anti-viral and anti-bacterial properties and stimulate muco-ciliary clearance, leading to improved congestion and the potential relief of other related symptoms. Our prior research has shown that acoustic vibrations trigger an increase in nitric oxide release from the sinuses and nasal passages,” said Dr. Rodney Schlosser, Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC) and co-Medical Director at SinuSonic. “We are eager to see whether regular use of SinuSonic during cold and flu season can decrease the chance of getting sick from one of these viruses.”

Medical studies unrelated to SinuSonic are already researching the positive effects of externally administering nitric oxide as a potential treatment for upper respiratory infections, including COVID-19. This latest SinuSonic independent study will take the theory a step further by measuring the body’s ability to prevent infection through harnessing its own natural production of nitric oxide spurred by using the SinuSonic device. Originally developed to treat chronic nasal congestion without drugs or mess, SinuSonic offers patients the ability to treat moderate to severe nasal congestion by simply breathing into a device, triggering the application of gentle acoustic vibrations and light resistant pressure to provide natural relief.

“A simple and inexpensive way of reducing viral respiratory infections would have tremendous impact for millions of Americans” stated Dr. Zachary Soler, Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina and co-Medical Director of SinuSonic. “Since its inception, SinuSonic has been committed to scientific inquiry. We are eager to bring participants on board into this real-world clinical trial.”

Results from an independent study published in the February 2020 edition of the International Forum of Allergy and Rhinology found more than 80 percent of trial subjects experienced clinically and statistically significant improvements in self-reported nasal congestion scores. Additionally, the SinuSonic device was found to be safe and well tolerated and improves objective AND subjective outcomes in chronic rhinitis. In fact, 87.5% of subjects would recommend SinuSonic to a friend or family member.

To participate in the study, applicants should email Caleb Pinkney at


Dr. Rodney Schlosser

Dr. Schlosser is the Director of Rhinology and Sinus Surgery at the Medical University of South Carolina (MUSC). After graduating from the U.S. Military Academy at West Point and serving for four years on active duty, Dr. Schlosser received his medical degree from the Mayo Clinic. He completed his ENT residency at the University of Virginia and then embarked on a one year fellowship at the University of Pennsylvania devoted to the treatment of advanced sinus disease.

Dr. Schlosser authored a textbook on the management of sinus problems and more than 200 articles and chapters on sinus and nasal topics. He regularly travels the world to speak and teach courses on the latest medical techniques, including endoscopic sinus surgery and computerized image-guided surgery. Dr. Schlosser focuses on difficult adult and pediatric sinus cases involving a host of conditions including nasal obstruction, revision surgeries, sinonasal tumors, encephaloceles/cerebrospinal fluid leaks, severe nasal polyposis, smell and taste disorders, and congenital nasal disorders.

Dr. Zachary Soler

Dr. Soler is an Associate Professor in the Division of Rhinology, also at the Medical University of South Carolina. He attended medical school at Wake Forest University, followed by an ENT residency at Oregon Health and Sciences University. He then completed a fellowship dedicated solely to rhinology and endoscopic sinus surgery at Harvard Medical School. Remaining at Harvard, Dr. Soler devoted an additional year of study, earning a master’s degree in epidemiology.

Dr Soler has published over 150 peer-reviewed articles, most of which focus on outcomes after treatment of diseases of the nose and sinuses. He is a principal investigator on a multi-center NIH study examining outcomes in patients with chronic sinusitis. Dr. Soler’s clinical practice is dedicated primarily to diseases of the nose, sinuses, and skull base. He has particular expertise with difficult-to-manage cases of sinusitis, revision sinus surgery, and surgical treatment of sinonasal tumors.

Though Dr. Schlosser and Dr. Soler are currently employed by the Medical University of South Carolina (MUSC), neither the Medical University of South Carolina, nor any affiliated organizations shall be responsible for information provided herein under any theory of liability or indemnity.


Founded in Columbia, South Carolina, and born through the research and partnerships of Richard K. Bogan, MD and David J. Lewis, SinuSonic is the first-ever patented nasal congestion relief device to use acoustic vibrations to help provide nasal congestion relief. SinuSonic is designed in the U.S. with parts molded in the U.S. and assembled in an FDA-registered facility in Columbia, South Carolina. Since launching in July 2019, SinuSonic is being used in all 50 states. For more information and to view instructional videos, visit

SCBIZtv is part of the SC Biz News family, serving 100,000 high-level business execs throughout South Carolina. Click for more from SCBIZtv.